PT  - JOURNAL ARTICLE
AU  - Fang, P
AU  - Wang, B C
AU  - Wu, C Y
AU  - Wan, W X
AU  - Jiang, N Y
AU  - Zhou, X
AU  - Chen, Z P
TI  - Pharmacology study of the neutral myocardial imaging agent technetium-99m-N(NOEt)2.
DP  - 1999 Mar 01
TA  - Journal of Nuclear Medicine Technology
PG  - 54--56
VI  - 27
IP  - 1
4099  - http://tech.snmjournals.org/content/27/1/54.short
4100  - http://tech.snmjournals.org/content/27/1/54.full
SO  - J. Nucl. Med. Technol.1999 Mar 01; 27
AB  - The biological properties of a new neutral myocardial imaging agent 99mTcN(NOEt)2 were evaluated.Blood clearance in rabbits, biodistribution in rats, and initial myocardial imaging in dogs were performed.Radiochemical purity of 99mTcN(NOEt)2 was more than 90% and stable for 6 h at room temperature. Blood disappearance was analyzed with a biexponential model and T1/2(alpha) = 2.53 min, T1/2(beta) = 330 min and CI = 378 ml/h were obtained. Biodistribution studies demonstrated that 99mTcN(NOEt)2 localized selectively in the rat myocardium. Cardiac uptakes were 4.69, 4.20, 3.95 and 3.43% ID/g at 5, 30, 60 and 90 min postinjection, respectively. The mean heart-to-lung activity ratios were 1.69, 2.40 and 2.55 at 10 min, 30 min and 60 min postinjection, respectively.Technetium-99m-N(NOEt)2 exhibited favorable stability and biological properties. Further study in humans is required.